Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and Lazertinib in Metastatic EGFR-mutant NSCLC with CNS Metastases
NCT04965090Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab, lazertinib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2021; status: completed.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04965090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965090.